G
Genexis Biotech
Animal-free proteins for healthcare and research applications
About Genexis Biotech
Genexis Biotech is a biotechnology company headquartered in Vadodara, Gujarat, India, focused on producing animal-origin-free biological solutions. The company manufactures a range of products using precision fermentation, including cytokines, growth factors, specialty proteins, cell culture media, and reagents. These products serve various sectors such as healthcare, pharmaceuticals, cellular agriculture, and research.
The firm's business model includes both product sales and specialized services. Their service offerings encompass strain engineering, metabolic engineering, process development and scale-up, and the creation of custom protein solutions tailored to client needs. By providing these high-purity, animal-free components, Genexis Biotech aims to support the global movement towards more ethical and sustainable scientific practices.
The company was co-founded by Nidhi Sapkal and Kuldeep Tyagi. Nidhi Sapkal, who serves as the CEO, has a background in Chemical Engineering with a Master's degree from New York University and has held roles at major pharmaceutical and biotech companies like Pfizer and Biogen. Kuldeep Tyagi, the COO, brings experience in bioprocess technology from his time at Intas Pharmaceuticals and Zydus Group, holding a Master's in Biotechnology. Their combined expertise in bioprocessing and biotechnology drives the company's research and development efforts in alternative proteins.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Vadodara, India
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 72.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Alternative Protein, Biotech and Pharma, Enabler of Alternative Proteins, Techbio, biomanufacturing, precision fermentation, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jul 2025 | $462K | $1.8M | Benzai10 · GVFL | ↗ |
Growth signals
Latest recorded traffic for Genexis Biotech is 870 monthly website visits, up 27.9% over the last three months. Genexis Biotech's team grew 44.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
GVFL
Benzai10
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genexis Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genexis Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.